Tango Therapeutics Q1 net loss widens as collaboration revenue falls

Tango Therapeutics

13/05/2026 21:23

Overview

US biotechnology firm's Q1 net loss widened as collaboration revenue fell to zero

Company's Q1 collaboration revenue fell to $0, compared to $5.4 mln last year

R&D expenses declined due to discontinued programs; G&A costs rose on personnel expenses

Outlook

Tango expects cash runway into 2028 beyond anticipated key data inflection points

Result Drivers

R&D SPENDING SHIFT - Decrease in R&D expenses attributed to discontinuation of TNG908 program and lower costs for TNG961 and discovery, partially offset by increased spending on vopimetostat and TNG456 clinical programs

NO COLLABORATION REVENUE - Collaboration revenue fell to zero after Gilead agreement ended and all deferred revenue was recognized in 2025

HIGHER ADMINISTRATIVE COSTS - G&A expenses rose due to increased personnel-related costs, including share-based compensation

Company press release: ID:nGNXbBsKqk

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.32
Q1 Net Income
-$45.51 mln
Q1 Basic EPS
-$0.32
Q1 Operating Expenses
$48.77 mln
Q1 Operating Income
-$48.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tango Therapeutics Inc is $20.50, about 12.8% below its May 12 closing price of $23.50

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)